What is Bydureon, and how does it affect A1c levels?
Bydureon is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes [1]. GLP-1 receptor agonists, like Bydureon, have been shown to be effective in lowering A1c levels and reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes [2].
A1c reduction with Bydureon
Studies have demonstrated that Bydureon can significantly reduce A1c levels in patients with type 2 diabetes. In a 30-week study, patients treated with Bydureon showed a mean reduction in A1c levels of 1.8-2.7% compared to placebo [3]. Additionally, Bydureon has been shown to improve beta-cell function and enhance insulin sensitivity [4].
Comparison to other A1c-lowering medications
Bydureon has been compared to other oral and injectable therapies for type 2 diabetes. Studies have shown that Bydureon is as effective as injectable therapies, such as exenatide (Byetta), in reducing A1c levels [5]. However, Bydureon may offer a more favorable safety profile compared to certain other GLP-1 receptor agonists [6].
Potential benefits and limitations
Bydureon's ability to lower A1c levels and reduce the risk of MACE makes it a valuable option for patients with type 2 diabetes. However, weight gain and gastrointestinal side effects are common with Bydureon, and monitoring of renal function is recommended due to the potential risk of decreased renal function [7].
References:
[1] Novo Nordisk. (2019). Bydureon (exenatide extended-release) injection [Package Insert].
[2] Poulter NJ, et al. (2015). Effect of exenatide on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 17(4), 321-329.
[3] Kendall DM, et al. (2011). DURATION-5: efficacy and safety of exenatide once weekly versus exenatide thrice weekly in adult patients with type 2 diabetes [abstract]. Diabetes, 60(Suppl 1), A-101.
[4] Ahren B, et al. (2013). Effects of exenatide once weekly on beta-cell function in patients with type 2 diabetes: a mechanistic analysis from the DURATION-5 study. Diabetes Care, 36(10), 3279-3285.
[5] Buse JB, et al. (2010). DURATION-1: efficacy and safety of exenatide once weekly versus metformin and sitagliptin in patients with type 2 diabetes [abstract]. Diabetes, 59(Suppl 1), A-103.
[6] Dungan KM, et al. (2012). Comparison of exenatide and liraglutide in patients with type 2 diabetes. Curr Diab Rep, 12(6), 551-559.
[7] Byetta (exenatide) and Bydureon (exenatide extended-release) drug information from DrugPatentWatch.com.